A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
← catalyst calendarSponsored by MacroGenics (industry) · MGNX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
31actual
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-19 | actual | When the study began enrolling |
| Primary completion | 2025-06-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-26 | actual | The whole study's end, after follow-up |
| First posted | 2022-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Castration-Resistant Prostatic Cancer
- Malignant Melanoma
- Pancreatic Ductal Carcinoma
- Hepatocellular Cancer
- Epithelial Ovarian Cancer
- Renal Cell Carcinoma
Interventions
- Biological: vobramitamab duocarmazine — also filed as MGC018
- Biological: lorigerlimab — also filed as MGD019
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 2 years
Number of participants with serious adverse events (SAEs)
measured Up to 2 years
Number of participants with AEs leading to study treatment discontinuation
measured Up to 2 years
Permalink · MGNX's whole pipeline · Catalyst calendar · Every registered study · What changed